A Structured Lipid Medical Food Product to Improve Gastrointestinal Function and Quality of Life in Patients with Pancreatic Neuroendocrine Tumor and Pancreatic Ductal Adenocarcinoma

Inclusion Criteria

• Pancreatic cancer (PC) or NET diagnosis and age ≥ 18 years
• For patients with NET, evidence of GI dysfunction such as > 5% unintentional weight loss, increased number of bowel movements, change in stool consistency (e.g., soft stool or diarrhea), or other GI dysfunction as determined by the treating medical oncologist. The specific GI dysfunction must be documented in the medical record and confirmed by the treating oncologist prior to enrollment. The documented dysfunction must have been present for a minimum of two weeks prior to enrollment
• Life expectancy of 4 months or greater per oncology team
• Oral or enteral tube feeding for > 60% daily calories, calculated as follows: Using the estimated energy requirement (EER) formulas from the National Academy of Medicine, we will calculate the subject's daily caloric need based on age, sex, height, weight, and a standardized physical activity coefficient (PAL). For patients with PDAC, we will use a PAL for "inactive," and for patients with NET, we will use a PAL for "low active." The caloric intake from oral sources and tube feeding will be determined by reviewing patient report and, for tube feeding, the prescription and caloric density of the specific formula, averaged over the last 7 days prior to enrollment
• No other disease that affects food intake or digestion

Exclusion Criteria

• Pregnant or lactating
• Unable to consume the SLMF powder in food/tube feeding
• Allergy to soy product ingredients
• Military service members, Reserve Service members, National Guard members, Department of Defense (DoD) civilians, and DoD contractors
• Psychosocial environment for which study participation may be difficult for subject or family, as confirmed by medical team
• Patients with diminished capacity to consent